Phototherapy, although effective for psoriasis in general populations, has been associated with photosensitive lupus activation and interferon-mediated cutaneous risk, indicating that its use in ANA-positive or lupus-spectrum disease should be individualized and phenotype-specific [9,20,38]. Here, BTG3 is linked to psoriasis.